✨ Medicines Notices




772 NEW ZEALAND GAZETTE, No. 29 30 MARCH 2006

Health

Medicines Act 1981

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product: Rapamune
Active Ingredient: Sirolimus 5mg
Dosage Form: Coated tablet
New Zealand Sponsor: Wyeth (NZ) Limited
Manufacturers: Wyeth Pharmaceuticals Company, Barrios Pozo Hondos & Jobos, Guayama, Puerto Rico
Wyeth Pharmaceuticals Inc, Rouses Point, New York, United States of America

Note: This consent is valid for two years from the date of publication of this notice.

Dated this 23rd day of March 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go2041

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Lyrinel XL
Active Ingredient: Oxybutynin hydrochloride 10mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Janssen-Cilag Pty Limited
Manufacturer: Alza Corporation, Mountain View, California, United States of America

Product: Lyrinel XL
Active Ingredient: Oxybutynin hydrochloride 15mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Janssen-Cilag Pty Limited
Manufacturer: Alza Corporation, Mountain View, California, United States of America

Product: Lyrinel XL
Active Ingredient: Oxybutynin hydrochloride 5mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Janssen-Cilag Pty Limited
Manufacturer: Alza Corporation, Mountain View, California, United States of America

Product: Metronidazole
Active Ingredient: Metronidazole 5mg/mL
Dosage Form: Solution for infusion
New Zealand Sponsor: AFT Pharmaceuticals Limited
Manufacturer: Claris Life Sciences Limited, Chacharwadi-Vasana, Ahmedabad, India

Product: Optrex Allergy Eyes
Active Ingredient: Sodium cromoglycate 2%w/v
Dosage Form: Eye drops, solution
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Tubilux Pharma SpA, Pomezia, Rome, Italy

Product: Sevoflurane
Active Ingredient: Sevoflurane 100%
Dosage Form: Volatile liquid for inhalation
New Zealand Sponsor: Baxter Healthcare Limited
Manufacturer: Baxter Healthcare Corporation of Puerto Rico, Guayama, Puerto Rico

Dated this 23rd day of March 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go2038



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2006, No 29


Gazette.govt.nz PDF NZ Gazette 2006, No 29





✨ LLM interpretation of page content

πŸ₯ Provisional Consent to Distribute New Medicine

πŸ₯ Health & Social Welfare
23 March 2006
Medicines, Provisional Consent, Rapamune, Sirolimus, Wyeth
  • DON MATHESON, Deputy Director-General, Public Health

πŸ₯ Consent to Distribute New Medicines

πŸ₯ Health & Social Welfare
23 March 2006
Medicines, Consent, Lyrinel XL, Oxybutynin hydrochloride, Metronidazole, Optrex Allergy Eyes, Sevoflurane
  • DON MATHESON, Deputy Director-General, Public Health